Search Results - "Montero, AJ"

Abstract P5-21-26: T-DM1 activity in metastatic HER2-positive breast cancer patients who have received prior trastuzumab and pertuzumab: NSABP B-005 by Tiwari, SR, Sussman, T, Kota, K, Moore, HC, Montero, AJ, Budd, GT, Puhalha, S, Abraham, J

“…Abstract Background : The pivotal phase III EMILIA trial reported a progression free survival (PFS) rate of 9.6 months and an objective response rate of 43%…”
Get full text

Abstract PD3-04: Analysis of ERBB2 (HER2) amplification by ctDNA in a phase Ib dose-escalation trial evaluating trastuzumab emtansine (T-DM1) with neratinib in women with metastatic disease with initially diagnosed HER2+ breast cancer: NSABP FB-10 by Abraham, J, Puhalla, SL, Sikov, WM, Montero, AJ, Salkeni, MA, Razaq, WA, Beumer, JH, Kiesel, BF, Buyse, ME, Adamson, LM, Srinivasan, A, Pogue-Geile, KL, Allegra, CJ, Nagy, RJ, Jacobs, SA

“…Abstract Background: In this phase Ib study, the activity of T-DM1 plus N was assessed in patients (pt) previously treated with trastuzumab, pertuzumab, and a…”
Get full text

Abstract P6-20-01: METRIC: A randomized international phase 2b study of the antibody-drug conjugate (ADC) glembatumumab vedotin (GV) in gpNMB-overexpressing, metastatic, triple-negative breast cancer (mTNBC) by Vahdat, LT, Forero-Torres, A, Schmid, P, Blackwell, K, Telli, ML, Melisko, M, Holgado, E, Moebus, V, Cortes, J, Fehrenbacher, L, Montero, AJ, Ma, C, Nanda, R, Wright, GS, He, Y, Bagley, RG, Halim, A, Turner, CD, Yardley, DA

“…Abstract Background gpNMB is an internalizable transmembrane protein overexpressed in ˜40% of TNBC, and associated with a worse prognosis. Preclinical data…”
Get full text

A Multi-Criteria Decision Making Approach for Selecting an Optimal Therapy for Metastatic Colorectal Cancer by Adunlin, G, Diaby, V, Campbell, ES, Xiao, H, Montero, AJ, Dranitsaris, G

Get full text

PCN202 - A Multi-Criteria Decision Making Approach for Selecting an Optimal Therapy for Metastatic Colorectal Cancer by Adunlin, G, Diaby, V, Campbell, ES, Xiao, H, Montero, AJ, Dranitsaris, G

Get full text

Phase 2 study of neoadjuvant treatment with NOV-002 in combination with doxorubicin and cyclophosphamide followed by docetaxel in patients with HER-2 negative clinical stage II–IIIc breast cancer by Montero, A. J., Diaz-Montero, C. M., Deutsch, Y. E., Hurley, J., Koniaris, L. G., Rumboldt, T., Yasir, S., Jorda, M., Garret-Mayer, E., Avisar, E., Slingerland, J., Silva, O., Welsh, C., Schuhwerk, K., Seo, P., Pegram, M. D., Glück, S.

“…NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and metastasis and enhances…”
Get full text

Abstract P6-09-03: Improved clinical outcomes associated with statin use during adjuvant chemotherapy in patients with HER2+ non-metastatic breast cancer by Zeichner, SB, Shah, NN, Montero, AJ, Gluck, S, Ahn, E

“…Abstract Background Statins are established as first line therapy in patients with hypercholesterolemia and are thought to have pleiotropic effects including…”
Get full text

Abstract P1-04-16: Multi-center experience with CELLSEARCH® circulating tumor cell kit on patients with metastatic breast cancer by Montero, AJ, Eapen, S, Tran, KN, Gorin, B, Adler, P

“…Abstract Background: Clinical studies have shown that circulating tumor cell (CTC) detection via the CELLSEARCH® assay is a validated prognostic marker for the…”
Get full text

Cost Effectiveness of Different Targeted Treatment Sequences for HER2-Positive Metastatic Breast Cancer by Diaby, V, Adunlin, G, Ali, A, Zeichner, S, Lopes, G, Kohn, CG, Montero, AJ

Get full text

PCN93 - Cost Effectiveness of Different Targeted Treatment Sequences for HER2-Positive Metastatic Breast Cancer by Diaby, V, Adunlin, G, Ali, A, Zeichner, S, Lopes, G, Kohn, CG, Montero, AJ

Get full text

COMPARATIVE COST-EFFECTIVENESS OF EARLY-STAGE BREAST CANCER TREATMENTS IN THE ELDERLY by Ali, AA, Xiao, H, Tawk, RH, Campbell, ES, Semykina, A, Montero, AJ, Diaby, V

“…OBJECTIVES: The aim of this study was to assess the comparative costeffectiveness of breast-conserving surgery plus hormonal therapy with or without…”
Get full text

Abstract P4-13-24: Impact of genomic medicine on clinical decision making in patients with advanced breast cancer at two academic medical centers by Kruse, ML, Santa-Maria, CA, Raska, P, Swoboda, A, Jain, S, Sohal, D, Moore, H, Budd, GT, Abraham, J, Montero, AJ

“…Abstract Background: A deeper molecular understanding of cancer biology has led to the development of therapies targeting driver mutations. Genomic profiling…”
Get full text

Abstract P6-09-02: Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ non-metastatic breast cancer by Zeichner, SB, Shah, NN, Montero, AJ, Markward, NJ, Gluck, S, Silva, O, Ahn, ER

“…Abstract Background Vitamin D (VitD) supplementation decreases the risk of osteoporotic fractures in the elderly; however, its extraskeletal benefits,…”
Get full text

Abstract P1-12-03: Low-dose capecitabine monotherapy in HER-2 negative metastatic breast cancer: a retrospective study by Ambros, T, Zeichner, SB, Zaravinos, J, Montero, AJ, Ahn, E, Mani, A, Kronish, L, Mahtani, RL, Vogel, CL

“…Abstract Background: Capecitabine (CAPE) has clinical activity in metastatic breast cancer (MBC) at an FDA approved dose of 1,250mg/m2 twice daily for 14 days…”
Get full text

Daily injections of the glutathione disulfide mimetic NOV-002 ameliorates hematologic toxicities from neoadjuvant chemotherapy in breast cancer patients enrolled in the NEO-NOVO trial, and significantly increases circulating dendritic cells by Diaz-Montero, C, Paphitis, N, Onicescu, G, Zhu, Y, Verma, N, Garrett-Mayer, E, Schuhwerk, KC, Pazoles, CJ, Glück, S, Montero, AJ

“…Abstract Abstract #2141 Background: Chemotherapy induced anemia is a common problem in breast cancer. Anemic events [Hgb<10 g/dL, use of erythropoietin…”
Get full text

Abstract P1-11-05: Phase 2 Study of Neoadjuvant Treatment with Cellular Redox Modulator NOV-002 in Combination with Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC→T) in Patients with Stage II-III HER-2 (-) Breast Cancer by Montero, AJ, Diaz, CM, Slingerland, J, Pegram, M, Hurley, J, Welsh, CF, Avisar, E, Seo, P, Vogel, CL, Garrett-Mayer, E, Hermann, V, Baker, MK, Silva, O, Koniaris, L, Rodgers, S, Schuhwerk, K, Pazoles, CJ, Moffat, F, Cole, DJ, Gluck, S.

“…Abstract Background: NOV-002 (a formulation of disodium glutathione disulfide) modulates signaling pathways involved in tumor cell proliferation and metastasis…”
Get full text

Drift Kinetic Equation Solver for Grid (DKEsG) by Rubio-Montero, Antonio Juan, Magaña, Francisco M Castejón, Rodríguez-Pascual, Manuel Aurelio, Prado, Esther Montes, García, Rafael Mayo

“…Neoclassical (NC) transport calculations are necessary for the complete simulation cycle of the behavior of plasmas inside both tokamaks and stellarators,…”
Get full text

Vulvar Langerhans cell histiocytosis: a case report and review of the literature by Santillan, Antonio, Montero, Alberto J, Kavanagh, John J, Liu, Jinsong, Ramirez, Pedro T

“…Langerhans cell histiocytosis (LCH) of the female genital tract is rare. Only, seven cases of primary vulvar LCH have been previously reported in the medical…”
Get full text

The natural history of breast carcinoma in patients with ≥ 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy : A multiinstitutional retrospective study by MONTERO, Alberto J, ROUZIER, Roman, ARRIAGADA, Rodrigo, SPIELMANN, Marc, GARCIA-CONDE, Javier, SAHIN, Aysegul A, SINGLETARY, Sonja E, HORTOBAGYI, Gabriel N, VALERO, Vicente, LLUCH, Ana, THERIAULT, Richard L, BUZDAR, Aman U, DELALOGE, Suzette, BERMEJO, Begonia, LE, Monique, KAU, Shu-Wan, DUNANT, Ariane

“…The majority of patients with breast carcinoma with > or = 10 metastatic axillary lymph nodes (ALNs) develop recurrent disease within 5 years from diagnosis…”
Get full text

Acute respiratory distress syndrome after rituximab infusion by MONTERO, Alberto J, MCCARTHY, John J, CHEN, George, RICE, Lawrence

“…Rituximab, a humanized monoclonal antibody approved for malignant lymphoma, is being increasingly, effectively, and safely used for immune thrombocytopenic…”
Get full text